EKF Diagnostics Holdings PLC Notice of Results and Investor Presentation
03 Septembre 2024 - 8:00AM
RNS Regulatory News
RNS Number : 5914C
EKF Diagnostics Holdings PLC
03 September 2024
EKF Diagnostics Holdings
plc
("EKF" or
the "Company")
Notice of Interim Results and
Investor Presentation
EKF Diagnostics Holdings plc (AIM:
EKF), the AIM-listed global diagnostics business,
will announce its interim
results for the six months ended 30 June 2024 on Tuesday 17
September 2024.
Investor Presentation
Julian Baines, Executive Chair, and
Stephen Young, Chief Financial Officer, will be hosting a live
online presentation relating to the interim results via the
Investor Meet Company (IMC) platform at 4.30pm (BST) on Wednesday 18 September
2024. The presentation is open to all existing and potential
investors.
Investors can sign up to IMC for
free and register for the presentation here:
https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor
Investors who already follow EKF on
the Investor Meet Company platform will automatically be
invited.
A recording of the presentation, a
PDF of the slides used, and responses to the Q&A session will
be available on the Investor Meet Company platform
afterwards.
|
EKF
Diagnostics Holdings plc
|
www.ekfdiagnostics.com
|
|
Julian Baines, Executive Chair /
Stephen Young, CFO
|
via Walbrook
PR
|
|
|
|
|
Singer Capital Markets (Nominated
Adviser & Broker)
|
Tel: +44
(0)20 7496 3000
|
|
Phil Davies / Oliver
Platts
|
|
|
|
|
|
Walbrook PR Limited
|
Tel: +44 (0)20 7933 8780
or ekf@walbrookpr.com
|
|
Paul McManus / Charlotte
Edgar
|
|
|
|
|
| |
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is an AIM-listed global
diagnostics business focussed on:
|
●
|
Point-of-Care analysers in
the key areas of Hematology and Diabetes
|
|
●
|
Life Sciences services
provide specialist manufacture of enzymes and custom products for
use in diagnostic, food and industrial applications.
|
EKF has headquarters in Penarth
(near Cardiff) and operates five manufacturing sites across the US
and Germany, selling into over 120 countries world-wide.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NORSSFFIEELSEIU
Ekf Diagnostics (LSE:EKF)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Ekf Diagnostics (LSE:EKF)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
